1-3 of 3
Peter O'Neill, MBA
Close
Sort by
Journal Articles

Primary Analysis Results from an Open-Label Phase II Study of INCB039110, a Selective JAK1 Inhibitor, in Patients with Myelofibrosis

John O Mascarenhas, MD MS, Moshe Talpaz, Vikas Gupta, MD FRCP, FRCPath, Lynda M Foltz, MD FRCP, Michael R Savona, MD, Ron Paquette, MD, Robert Turner, MD, Paul Coughlin, PhD MBBS, Elliott Winton, MD, Deborah Hunter, PhD, Albert Assad, MD, Jason Clark, PhD, Peter O'Neill, MBA, CCRP, Ronald Hoffman, MD, Srdan Verstovsek, MD PhD
Journal: Blood
Blood (2014) 124 (21): 714.
https://doi.org/10.1182/blood.V124.21.714.714
Published: 2014
Journal Articles

An Open-Label, Phase II Study Of The JAK1 Inhibitor INCB039110 In Patients With Myelofibrosis

John Mascarenhas, MD, Moshe Talpaz, MD, Vikas Gupta, MD, FRCP, FRCPath, Michael Savona, MD, FACP, Paul Coughlin, FRACP, PhD, Elliott Winton, MD, Deborah Hunter, PhD, Bijoyesh Mookerjee, MD, FACP, Lance Leopold, MD, Jason Clark, PhD, Peter O'Neill, MBA, CCRP, Ronald Hoffman, MD, Srdan Verstovsek, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 663.
https://doi.org/10.1182/blood.V122.21.663.663
Published: 2013
Journal Articles

Efficacy, Hematologic Effects, and Dose of Ruxolitinib in Myelofibrosis Patients with Low Starting Platelet Counts (50–100 × 10 9 /L): A Comparison to Patients with Normal or High Starting Platelet Counts

Moshe Talpaz, MD, Ronald Paquette, MD, PhD, Lawrence Afrin, MD, Solomon Hamburg, MD, PhD, Katarzyna Jamieson, MD, Howard Terebelo, DO, Gregory Ortega, MD, Roger M. Lyons, MD, Ramon V. Tiu, MD, BS, Elliott F. Winton, MD, Kavita Natrajan, MD, Olatoyosi Odenike, MD, Wei Peng, PhD, Victor A. Sandor, MD, CM, Peter O'Neill, MBA, CCRP, Sue Erickson-Viitanen, PhD, Lance Leopold, MD, Richard S Levy, MD, Hagop M Kantarjian, MD, Srdan Verstovsek, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 176.
https://doi.org/10.1182/blood.V120.21.176.176
Published: 2012